Vigil Neuroscience (NASDAQ:VIGL) Price Target Cut to $14.00 by Analysts at HC Wainwright

Vigil Neuroscience (NASDAQ:VIGL) had its target price decreased by HC Wainwright from $17.00 to $14.00 in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

VIGL has been the topic of a number of other reports. Guggenheim reiterated a “buy” rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. William Blair began coverage on Vigil Neuroscience in a research report on Wednesday, December 4th. They issued an “outperform” rating on the stock. Finally, JMP Securities reiterated a “market outperform” rating and issued a $22.00 price objective on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $16.25.

Vigil Neuroscience Price Performance

VIGL stock opened at $2.02 on Friday. The business has a fifty day moving average price of $2.34 and a 200 day moving average price of $2.78. Vigil Neuroscience has a fifty-two week low of $1.49 and a fifty-two week high of $6.06. The stock has a market capitalization of $82.58 million, a price-to-earnings ratio of -0.98 and a beta of 1.82.

Vigil Neuroscience (NASDAQ:VIGL) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08). On average, equities analysts expect that Vigil Neuroscience will post -2.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC boosted its position in shares of Vigil Neuroscience by 53.0% in the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock worth $41,000 after purchasing an additional 8,358 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Vigil Neuroscience in the 4th quarter worth $83,000. Barclays PLC boosted its position in shares of Vigil Neuroscience by 43.6% in the 4th quarter. Barclays PLC now owns 64,049 shares of the company’s stock worth $109,000 after purchasing an additional 19,436 shares during the last quarter. Northern Trust Corp boosted its position in shares of Vigil Neuroscience by 29.0% in the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock worth $110,000 after purchasing an additional 14,572 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its position in shares of Vigil Neuroscience by 243.8% in the 4th quarter. Two Sigma Advisers LP now owns 69,100 shares of the company’s stock worth $117,000 after purchasing an additional 49,000 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.